DelveInsight’s “Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast — 2032” report delivers an in-depth understanding of the Acute Myeloid Leukemia, historical and forecasted epidemiology as well as the Acute Myeloid Leukemia market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

 

Key Takeaways from the Acute Myeloid Leukemia Market Research Report

• The increase in Acute Myeloid Leukemia Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Acute Myeloid Leukemia market is anticipated to witness growth at a considerable CAGR.
• The leading Acute Myeloid Leukemia Companies working in the market include Pfizer, Bristol Myers Squibb, Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Pfizer, Novartis Oncology, Daiichi Sankyo., Bristol Myers Squibb, AstraZeneca/Aex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum/DCPrime BV, GT Biopharma Inc, Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Actinium Pharmaceuticals, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen Inc, AGC Biologics S.p.A., Precigen Inc, Novartis Pharmaceuticals, Xencor, Inc./Novartis, Celgene/Bristol Myers Squibb, and others.
• Promising Acute Myeloid Leukemia Pipeline Therapies in the various stages of development include Fosciclopirox + Cytarabine, CPX-351, Minnelide, SNDX-5613, ASTX727, KPT-9274, SAR445419, ADI-PEG 20, BP1002, CTX-712, BTX-A51, PRGN-3006 T Cells, LY3214996, Regorafenib, GDX012, MRX-2843, SC-DARIC33, CWP232291, TL-895, KRT-232, CYAD-02, MK-0482, and others.
• April 2024: AbbVie announced a study of Phase 1 clinical trials for ABBV-787. A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-787 in Adult Subjects with Acute Myeloid Leukemia (AML).
• April 2024: Kite, A Gilead Company announced a study of Phase 1 clinical trials for Cyclophosphamide, and Fludarabine. The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).
• April 2024: Astex Pharmaceuticals Inc. announced a study of Phase 1 & 2 clinical trials for Decitabine and Cedazuridine (ASTX727) and Venetoclax. The Phase 1 portion of this study is a single-arm, open-label, multicenter, non-randomized interventional study to evaluate the pharmacokinetic (PK) interaction, safety, and efficacy of ASTX727 when given in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. The primary purpose of the study is to rule out drug-drug interactions between ASTX727 and venetoclax combination therapy by evaluating area under the curve (AUC) and maximum plasma concentration (Cmax) exposure.

 

Discover which therapies are expected to grab the Acute Myeloid Leukemia Market Share @ Acute Myeloid Leukemia Market Outlook

 

Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML) (also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukaemia) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. AML can involve tissues outside the bone marrow and blood, including lymph nodes, the brain, skin, and other parts of the body.

 

Acute Myeloid Leukemia Epidemiology Insights

The epidemiology section of Acute Myeloid Leukemia offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

• Total Acute Myeloid Leukemia Incident Cases
• Acute Myeloid Leukemia Age-specific Cases
• Acute Myeloid Leukemia Gender-specific Cases
• Acute Myeloid Leukemia Mutation-specific Cases

 

Download the report to understand which factors are driving Acute Myeloid Leukemia Epidemiology trends @ Acute Myeloid Leukemia Epidemiological Insights

 

Acute Myeloid Leukemia Drugs Market

The Acute Myeloid Leukemia Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Acute Myeloid Leukemia signaling in Acute Myeloid Leukemia are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Acute Myeloid Leukemia Treatment Market Landscape

The Acute Myeloid Leukemia treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Acute Myeloid Leukemia has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Acute Myeloid Leukemia treatment guidelines, visit @ Acute Myeloid Leukemia Treatment Market Landscape

 

Acute Myeloid Leukemia Market Outlook

The report’s outlook on the Acute Myeloid Leukemia market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Acute Myeloid Leukemia therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Acute Myeloid Leukemia drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Acute Myeloid Leukemia market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Acute Myeloid Leukemia Drugs Uptake

The drug chapter of the Acute Myeloid Leukemia report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Acute Myeloid Leukemia.

 

Major Acute Myeloid Leukemia Companies

Several Acute Myeloid Leukemia Companies working in the market include Pfizer, Bristol Myers Squibb, Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Pfizer, Novartis Oncology, Daiichi Sankyo., Bristol Myers Squibb, AstraZeneca/Aex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum/DCPrime BV, GT Biopharma Inc, Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Actinium Pharmaceuticals, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen Inc, AGC Biologics S.p.A., Precigen Inc, Novartis Pharmaceuticals, Xencor, Inc./Novartis, Celgene/Bristol Myers Squibb, and others.

 

Learn more about the FDA-approved drugs for Acute Myeloid Leukemia @ Drugs for Acute Myeloid Leukemia Treatment

 

Scope of the Acute Myeloid Leukemia Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Acute Myeloid Leukemia Companies- Pfizer, Bristol Myers Squibb, Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Pfizer, Novartis Oncology, Daiichi Sankyo., Bristol Myers Squibb, AstraZeneca/Aex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum/DCPrime BV, GT Biopharma Inc, Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Actinium Pharmaceuticals, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen Inc, AGC Biologics S.p.A., Precigen Inc, Novartis Pharmaceuticals, Xencor, Inc./Novartis, Celgene/Bristol Myers Squibb, and others.
• Acute Myeloid Leukemia Pipeline Therapies- Fosciclopirox + Cytarabine, CPX-351, Minnelide, SNDX-5613, ASTX727, KPT-9274, SAR445419, ADI-PEG 20, BP1002, CTX-712, BTX-A51, PRGN-3006 T Cells, LY3214996, Regorafenib, GDX012, MRX-2843, SC-DARIC33, CWP232291, TL-895, KRT-232, CYAD-02, MK-0482, and others.
• Acute Myeloid Leukemia Market Dynamics: Acute Myeloid Leukemia Market Drivers and Barriers
• Acute Myeloid Leukemia Market Access and Reimbursement, Unmet Needs, KOL’s Views, and Analyst’s Views

 

Discover more about Acute Myeloid Leukemia Drugs in development @ Acute Myeloid Leukemia Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary of Acute Myeloid Leukemia (AML)

3. Competitive Intelligence Analysis for Acute Myeloid Leukemia (AML)

4. Acute Myeloid Leukemia (AML): Market Overview at a Glance

5. Acute Myeloid Leukemia (AML): Disease Background and Overview

6. Patient Journey

7. Acute Myeloid Leukemia (AML) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Myeloid Leukemia (AML) Unmet Needs

10. Key Endpoints of Acute Myeloid Leukemia (AML) Treatment

11. Acute Myeloid Leukemia (AML) Marketed Products

12. Acute Myeloid Leukemia (AML) Emerging Therapies

13. Acute Myeloid Leukemia (AML): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Acute Myeloid Leukemia (AML)

17. KOL Views

18. Acute Myeloid Leukemia Market Drivers

19. Acute Myeloid Leukemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/